56 results about "Immune signaling" patented technology

The invention relates to the technical field of biology, in particular to application of a rice OsPBL8 gene in enhancing resistance of rice to magnaporthe oryzae. The rice OsPBL8 gene is a rice endogenous gene participating in the processes of plant growth and development, abiotic stress response, hormone signal channel regulation and control and the like. The invention provides application of the OsPBL8 gene in the field of disease resistance, the OsPBL8 gene is overexpressed through gene editing, and the expression quantity of receptor-like cytoplasm kinase OsPBL8 in plants is increased, so that a plurality of signal channels are regulated and controlled, and the germ resistance of the plants is synergistically improved. By adjusting key hub nodes of plant targeted immune signal transduction, more lasting broad-spectrum disease resistance can be provided, good universality is achieved, disease resistance and growth can be balanced, good practicability is achieved, and improvement of disease resistance of various rice varieties is facilitated.

The invention provides a cobalt monatomic nano-enzyme system modified by phospholipid polyethylene glycol carboxyl. The cobalt monatomic nano-enzyme system comprises a cobalt monatomic nano-enzyme composite core and phospholipid polyethylene glycol carboxyl compounded on the surface of cobalt monatomic nano-enzyme, the cobalt monatomic nano-enzyme composite core comprises a cobalt monatomic nano-enzyme and ginsenoside loaded on the cobalt monatomic nano-enzyme. The invention also provides a bifidobacterium synergetic cobalt monatomic nano-enzyme system which is formed by combining cobalt monatomic nano-enzyme with ginsenoside Rb1 and further delivering the cobalt monatomic nano-enzyme and ginsenoside Rb1 through bifidobacterium bifidum for targeted therapy of enteritis. The combination of Co SA and Rb1 can enhance the anti-inflammatory efficacy by adjusting a key immune signal pathway, and bifidobacterium bifidum can ensure targeted delivery of microbiota and promote intestinal barrier repair. The synergistic three-component strategy integrating monatomic nano-enzyme antioxidation, natural drug immunoregulation and probiotic targeting is provided, and a promising treatment platform is provided for accurate intervention of IBD.

The invention relates to a recurrent abortion early-warning method based on maternal and fetal immune interaction characteristics, which comprises the following steps: by taking decidua immune cells and trophoblasts as a unit, defining the regulation intensity of a key path of a path in an immune receptivity state; evaluating the coordination degree of signals among different cells by utilizing an information theory method; introducing a maternal and fetal immune receptivity steady-state index UISI; through continuous time sampling analysis, an immune signal offset track is identified; establishing an interactive imbalance index (IEI), and quantifying the imbalance intensity; designing a disturbance and response test; fitting the response trend of the IEI change to the disturbance into a system response curve IRC, and quantifying the recovery capability of the immune system; the IRC and individual clinical features are fused, and a dynamic risk thermodynamic relation is established; intervention window weight factors are constructed, wherein the intervention window weight factors comprise the fluctuation amplitude, the recovery period and the UISI critical value proximity; outputting a dynamic intervention suggestion map, and prompting a doctor to observe a period and a drug intervention starting point; the early warning capability is strong, and the limitation of traditional passive diagnosis is broken through.

The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV / Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV / Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV / Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV / Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV / Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV / Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV / Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV / Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APCs.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

The invention discloses a multi-compartment delay differential modeling method for simulating alpha nuclide synergy immunotherapy. The method comprises the following steps: S1, establishing a dual-channel immune attraction signal containing two tumor compartments, two lymphocyte compartments and a dual-channel immune attraction signal; s2, calculating the survival rate # imgabs0 # of the tumor cells under alpha nuclide radiation by adopting a high LET correction linear quadratic model; s3, quantifying delay effects from tumor cell injury / death to immune signal release and from immune signal to lymphocyte collection by using Gamma distribution kernel functions # imgabs1 # and # imgabs2 #; and S4, establishing a bidirectional dynamic transformation mechanism of the immunosuppressive lymphocyte Li and the immunocompetent lymphocyte La, wherein the transformation rate is jointly regulated by an immunocompetent signal # imgabs3 #, an immunosuppressive signal # imgabs4 # and an immunotherapeutic drug regulation function # imgabs5 #. The defects in the prior art are overcome, and high LET radiation kinetics, a time delay mechanism, immune cell subset plasticity and an immunotherapy intervention effect can be considered at the same time.

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

The invention belongs to the technical field of biology, and particularly relates to lactobacillus rhamnosus YDJ-05 as well as a targeted delivery composition and application of the lactobacillus rhamnosus YDJ-05. The invention provides a lactobacillus rhamnosus YDJ-05. The lactobacillus rhamnosus strain is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on April 11, 2025, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.34174. The lactobacillus rhamnosus YDJ-05 has the advantages that the lactobacillus rhamnosus YDJ-05 can be used for preparing the lactobacillus rhamnosus YDJ-05, and the lactobacillus rhamnosus YDJ-05 can be used for preparing the lactobacillus rhamnosus YDJ-05; meanwhile, the invention provides a target delivery composition and application of the rhamnosus cheese bacillus YDJ-05, the YDJ-05 strain is a newly separated and preserved strain, plays an anti-inflammatory role by regulating and controlling a specific immune signal channel and is clear in mechanism, and moreover, the double-layer polysaccharide hydrogel delivery system adopted by the invention has the advantages that the anti-inflammatory effect is achieved, and the application range is wide. The survival rate of thalli in a gastric acid environment can be remarkably improved, rapid and accurate release in an intestinal environment is realized, and the utilization efficiency of probiotics is greatly improved.

The present invention relates to T cell receptors (TCRs) for the cancer / testis antigens NY-ESO-1 and CT83, which are presented by multiple HLA molecules. Preferred TCRs of the present invention, derived from human T cells, exhibit high affinity and antigen specificity in vitro and in vivo. The present invention also relates to modulation of TCR-T CAR-T cell signaling and functional persistence in cancer immunotherapy. In one aspect, the present disclosure relates to methods for identifying and functionally validating TCRs from cancer antigen-specific T cells.

Described herein is a DNA nanostructure-based platform that can modulate a number of cellular functions depending on the concentration and surface decoration of the nanostructure. Utilizing different peptides for surface functionalization of DNA nanostructures, lysosomal activity was able to be modulated which in turn translated into the control of cellular functionality, ranging from changes in cell morphology to modulation of immune signaling and cell death. This demonstrates the rational design of a new generation of versatile DNA-based nanoplatforms that can be used in various biomedical applications such as the development of combinatorial anti-cancer platforms, efficient systems for endolysosomal escape, and nanoplatforms modulating lysosomal pH.

The invention discloses an application of a protease cleavage site mutant of a natural immune signal linker protein MAVS in resisting African swine fever viruses, aiming at three sites of African swine fever protease pS273R cleavage MAVS, the research finds that the site mutant can efficiently inhibit the replication of the African swine fever viruses; and breeding the variety pigs capable of resisting African swine fever by utilizing a gene editing technology.

Provided are a chemokine CXCL12 fusion protein and a use thereof. The chemokine CXCL12 fusion protein comprises the chemokine CXCL12 and an antibody against a tumor-associated antigen. The chemokine CXCL12 and the antibody against the tumor-associated antigen are directly fused or fused by means of a linker. On the one hand, the provided chemokine CXCL12 fusion protein can promote T cell infiltration and improve targeting. On the other hand, T cell killing signals are highly dependent on target cells, and T cells generate immune signals to kill the target cells only upon coming into contact with the target cells under the mediation of the fusion protein, thereby reducing toxic side effects.

The present invention discloses a cyclic sugar phosphate compound and its application. The compound is shown in Formula I. Experimental studies have confirmed that the compound can provide carbon source nutrition for Xanthomonas bacteria and has the ability to broadly inhibit plant basal defense responses induced by various immune elicitors, including reactive oxygen species bursts and upregulated expression of pathogenesis-related (PR) genes, providing an effective tool for studying plant immune signaling pathways. #imgabs0#

To provide antigen-specific T cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy.SOLUTION: The present invention relates to T cell receptors (TCRs) against cancer / testis antigens NY-ESO-1 and CT83 presented by multiple HLA molecules. Preferred TCRs of the invention derived from human T cells exhibit high affinity and antigen specificity in vitro and in vivo. The present invention also relates to modulation of TCR-T CAR-T cell signaling and functional persistence in cancer immunotherapy. In one aspect, the disclosure relates to methods for identifying and functionally validating TCRs from cancer antigen-specific T cells.SELECTED DRAWING: None

The invention discloses a lateral flow chromatography test strip for immunosignal replacement based on electrochemical detection as well as a preparation method and application of the lateral flow chromatography test strip. The test strip comprises a sample pad, a capture antibody pad, a solid-phase protein film, a detection electrode and a signal amplification pad, a capture antibody with a label is fixed on the capture antibody pad and can be combined with an antigen in a sample to form an antigen-antibody compound; solid-phase protein is fixed on the solid-phase protein film and can be combined with an antigen in an antigen-antibody compound; and a target object which can be combined with a label for capturing an antibody is fixed on the signal amplification pad. According to the invention, through the replacement signal of the immune lateral flow of the antigen and the antibody, the antibody which can reflect the antigen amount and is provided with the marker generates an electric signal at the tail end of the lateral flow or is catalyzed and amplified by the marker to generate a strong electrochemical signal, so that the detection accuracy and sensitivity can be obviously improved; and interference signals of electrochemical detection based on immunoreaction are obviously reduced.

A multi-compartment delayed differential modeling method for simulating alpha-nuclides synergistic immunotherapy includes: S1, establishing two tumor compartments, two lymphocyte compartments, and a dual-channel immune attraction signal; S2, using a high-LET modified linear quadratic model to calculate tumor cell survival rate under alpha-nuclides radiation; S3, using the Gamma distribution kernel function to quantify the delayed effect from tumor cell damage / death to immune signal release, and from immune signal to lymphocyte recruitment; S4, establishing a bidirectional dynamic conversion mechanism of immunosuppressive lymphocytes Li and immune-promoting lymphocytes La, where the conversion rate is jointly regulated by immune-promoting and immune-suppressing signals and immunotherapy drug control functions. The present invention overcomes the shortcomings of the existing technology and can simultaneously take into account high-LET radiation dynamics, time delay mechanisms, immune cell subset plasticity, and immunotherapy intervention effects.

The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The application relates to the technical field of biomedical engineering, and particularly discloses a method for extracting binary condensate immune signals, which comprises the following steps: screening disease-related high-expression genes by using a disease model, a normal model and a drug treatment model; screening important protein molecules based on the high-expression genes by using a nucleic acid-protein affinity analysis method; constructing a fusion carrier based on cytoskeleton proteins, important protein molecules and green fluorescent protein tracing; and identifying risk genes and possible downstream proteins associated with condensates by spatial omics imaging based on the fusion carrier of the disease model, the normal model and the drug treatment model, and quantifying the condensation process of the condensates. The application reduces the influence of problems such as condensate state destruction and spatial distribution information loss, and accurately realizes in-situ spatial omics imaging and analysis of an immune microenvironment evolution process of a complex disease.

This invention relates to T-cell receptors (TCRs) targeting the cancer / testis antigens NY-ESO-1 and CT83 presented by various HLA molecules. Preferred TCRs of this invention are derived from human T cells and exhibit high affinity and high antigen specificity both in vitro and in vivo. Furthermore, this invention also relates to the regulation of TCR-T and CAR-T cell signaling and their functional persistence in cancer immunotherapy.

The invention discloses a space-time controllable activated vaccine adjuvant, a vaccine as well as preparation methods and applications of the space-time controllable activated vaccine adjuvant and the vaccine. The vaccine adjuvant disclosed by the invention is formed by co-assembling polypeptide, a light / sound sensitive agent and a congenital immune signal agonist. The space-time controllable activated vaccine adjuvant disclosed by the invention can further entrap multiple disease type antigens to prepare a vaccine, controls and activates an antigen presenting cell innate immune signal channel through exogenous near-infrared light / ultrasound, induces I-type interferon secretion and enhances the antigen presenting efficiency so as to activate strong antigen specific cellular immune and humoral immune response, and can be used for preparing the vaccine. Therefore, tumor growth and metastasis are effectively inhibited, and the compound is expected to be further applied to prevention of infectious diseases.

The invention provides construction and application of a PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) attenuated vaccine double-gene mutant strain, the PRRSV attenuated vaccine double-gene mutant strain weakens the inhibition effect of PRRSV coding non-structural protein on an I-type IFN innate immune signal channel, and mutates amino acid sites with potential immunosuppression effect on non-structural proteins Nsp11 and Nsp12 in a PRRSV HuN4-F112 strain, so as to obtain the PRRSV attenuated vaccine double-gene mutant strain. According to the method, mutant genes maNsp11 and maNsp12 are obtained, on the basis, the double-gene mutant strain vmaNsp1112 is successfully rescued and obtained by utilizing a reverse genetic manipulation technology, and the obtained double-gene mutant strain has genetic stability in an in-vitro passage process, and particularly, compared with a parent strain, the double-gene mutant strain has the advantages that the double-gene mutant strain has the advantages that the yield is high; the double-gene mutation strain vmaNsp1112 can significantly weaken the inhibition effect on the activity of an I-type IFN promoter, a novel genetic engineering vaccine candidate strain with the innate immunosuppression reduction effect is developed, and a foundation is laid for improving the immune efficacy of an existing vaccine and effectively preventing and controlling PRRSV.

The present invention relates to the use of PACSIN2 in promoting activation of the STING signaling pathway. This invention fully demonstrates that PACSIN2 can effectively promote activation of the type I interferon-mediated innate immune network, particularly participating in STING transport and promoting STING-mediated activation of the type I interferon pathway. At the effector level, it is confirmed that exogenously overexpressing PACSIN2 in immune cell systems can significantly enhance the response of the STING signaling pathway, providing an effective solution for improving the therapeutic efficacy of diseases requiring innate immune activation. The discovery of this innovative mechanism for achieving sustained activation of the innate immune response in the tumor microenvironment and the implementation of a targeted strategy will overcome the difficulty in activating innate immune signals in tumor cells, providing an important scientific basis for achieving the "cold-hot" transition of tumor cells.

The present disclosure provides chimeric proteins capable of activating immune signaling and nucleic acid sequences and expression vectors encoding the proteins, cells expressing the proteins, and methods of using the same.

This application discloses the application of the TaFIPR-D gene or biological materials containing the TaFIPR-D gene in enhancing plant resistance to fungal diseases. By increasing the content level of the receptor-like kinase protein TaFIPR in plant cells, this application enhances the recognition of the polypeptide TaFIP, which is beneficial for expanding disease-resistant immune signals, thereby effectively improving plant resistance to Fusarium graminearum and / or Fusarium pseudograminearum.

The invention relates to a degradant motif in a natural immune signal channel and application of the degradant motif. According to the invention, through comparative analysis of key molecules RIG-I and MDA5 in an RLR signal channel and protein sequences, conservative KENW or KEHW or KEDW motifs exist in CARD structural domains of the key molecules RIG-I and MDA5; and a gene engineering means is further utilized to carry out deletion and point mutation on the "KENW" or "KEHW" or "KEDW" motif, which verifies that the motif is necessary for "activation" and "closing" of RIG-I and MDA5 signal pathways, and proves that the motif is a degradation submotif in a natural immune signal pathway. The invention also proves that the E3 ubiquitin ligase RNF20 can specifically recognize the motif and is used for regulating and controlling the immune homeostasis mediated by the RLR signal channel, so that the E3 ubiquitin ligase RNF20 can be used for treating immune-related diseases caused by the RLR signal channel.

The invention relates to the technical field of plant genetic engineering and molecular breeding, in particular to application of an OsCIPK29 gene in enhancing rice blast resistance of rice. The CIPK protein kinase is an important calcium signal decoding factor in plants and plays a key role in calcium signal transduction, adversity stress response and immune signal regulation. According to the application, the expression level of the OsCIPK29 gene in the rice is regulated and controlled by a molecular biology means, so that the immune response capability of the rice under a pathogenic bacterium infection condition is regulated and controlled, and the resistance of the rice to pathogenic bacteria such as rice blast is further improved. Transgenic rice obtained by transferring the OsCIPK29 gene into initial rice shows excellent broad-spectrum property and persistent disease resistance. And the problems of unstable resistance and easy loss in the existing breeding method are effectively solved.

The invention belongs to the technical field of biological pharmacy and protein engineering, and particularly relates to a TNFRSF13C mutant, a humanized fusion protein thereof and application of the TNFRSF13C mutant. The invention provides a TNFRSF13C mutant and a TNFRSF13C mutant-Fc fusion protein, wherein the amino acid sequences of the TNFRSF13C mutant and the TNFRSF13C mutant-Fc fusion protein are respectively shown as SEQ ID NO.3 and SEQ ID NO.10. The invention also provides a preparation method of the The mutant and the fusion protein have higher binding affinity with BAFF, are stable in structure and simple and convenient to prepare, can be specifically bound with BAFF and participate in regulation and control of BAFF-mediated immune signals, have important application value in regulation of B cell functions and maintenance of immune homeostasis, and provide novel molecular and technical support for related research and development of immune regulation and control.